Shares of Insilico Medicine (03696) rose more than 6% against the broader market trend. At the time of writing, the stock was up 6.65% to HK$35.92, with a turnover of HK$48.60 million.

The catalyst for the move was the recent initiation of an investigator meeting for the Phase III clinical trial of Rentosertib (also known as ISM001-055) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Rentosertib represents the company's most advanced pipeline asset and is noted as the world's first drug candidate discovered and designed entirely by generative artificial intelligence to have completed a Phase IIa clinical study.

An analysis from Southwest Securities highlighted the significant market potential for IPF treatments. The report suggested that if ISM001-055 successfully reaches the market, it could establish itself as a transformative therapy. The firm anticipates that as more pipeline assets advance into clinical stages and are licensed out, the company is positioned for sustained value realization.

The analysis further stated that the progression of this core asset through clinical trials will provide continued validation of the company's AI-driven research and development capabilities.